Novel eye drug delivery and release system

Abstract

The utility model provides a novel eye drug delivery and release system which sequentially comprises a main body base layer and a waterproof isolation layer from outside to inside, the main body base layer and the waterproof isolation layer are fixedly attached together, and at least one drug storage and release layer is attached to the waterproof isolation layer. The medicine storage and release layer is used for storing ophthalmology medicine and releasing the ophthalmology medicine into eyes when the ophthalmology medicine is in contact with the eyes, the medicine storage and release layer comprises a base layer and an upper layer which are attached together, the base layer is a methyl cellulose layer, and the upper layer is a polycaprolactone layer. According to the utility model, medicine is administrated on the bitamporal sides of two eyes, and medicine quickly passes through the lower lacrimal punctum, so that medicine loss is reduced; a patient does not need to directly face the medicine bottle, fear of the patient is reduced, and the medicine bottle is prevented from touching eyes by mistake; the disposable liquid medicine bottle is disposable, high in comfort level, convenient to operate, capable of being used in cooperation with most of liquid medicine and high in applicability. The effective duration and concentration of eyelid margin medication can be increased, and the effectiveness is higher; the eye cleaning device has various functions and can also be used for cleaning eye conjunctival sacs and eyelid margins.

Description

Technical Field

[0001] This utility model relates to the field of ophthalmic drug delivery devices, and in particular to a novel ophthalmic drug delivery and release system. Background Technology

[0002] Existing methods of ocular drug delivery include: traditional eye drops, gels, and ointments; subconjunctival injection; peribulbar and retrobulbar injection; intravitreal injection; and systemic drug administration. New research and approaches include: 1. Drug delivery devices (contact lenses, punctal plugs, anterior chamber drug-eluting implants, conjunctival fornix implants); 2. Nanoparticle materials (chitosan and its composites, gelatin and its composites, polyester polymers); 3. Liposomes.

[0003] Existing drug delivery methods have several problems in clinical application: 1. Traditional eye drops, gels, and ointments present challenges such as resistance and non-compliance in children, inconsistent use in adults, and the risk of bottle contamination. 2. Topical application of eye drops, gels, and ointments results in low drug bioavailability, and the drugs can reflexively increase tear secretion, causing 70%–80% of the drug to be expelled through the nasolacrimal duct or overflow from the eye, leading to fluctuating drug concentrations in the eye. 3. Systemic medication for eye diseases encounters the blood-eye barrier; increasing dosage can cause systemic side effects and first-pass metabolism. 4. Newer drug delivery methods are expensive, require specialized medical personnel, and are suitable for chronic, long-term instillation patients, but not for general, short-term use. Utility Model Content

[0004] In response to the above-mentioned issues, this invention proposes a novel ocular drug delivery system that addresses problems such as improper patient medication use, lack of cooperation from children, low duration of medication application along the eyelid margin, and low effective concentration.

[0005] The technical solution of this utility model is implemented as follows:

[0006] A novel ocular drug delivery system comprises, from the outside to the inside, a main body base and a waterproof isolation layer fixedly bonded together. At least one drug storage and release layer is bonded to the waterproof isolation layer. The drug storage and release layer is used to store ophthalmic drugs and release them into the eye upon contact with the eye. The drug storage and release layer includes a base layer and an upper layer bonded together. The base layer is a methylcellulose layer, and the upper layer is a polycaprolactone layer. The waterproof isolation layer is used to prevent water and bacteria from entering the drug storage and release layer from the main body base.

[0007] Furthermore, a cleaning and protective layer is also attached to the waterproof isolation layer. The cleaning and protective layer is used to clean the eyes after water drips and to protect the eyes from contact with the waterproof isolation layer.

[0008] Furthermore, the cleaning and protective layer is medical non-woven fabric or medical cotton fabric.

[0009] Furthermore, the main base layer, the waterproof isolation layer, and the cleaning and protective layer have the same shape.

[0010] Furthermore, the main base layer is shaped like an eye mask or an oval.

[0011] Furthermore, the main base layer is printed fabric, non-woven fabric, plain fabric, or elastic fabric.

[0012] Furthermore, the waterproof isolation layer is a PU film, PE film, or PP film.

[0013] Furthermore, the drug storage and release layer is elliptical or circular.

[0014] Furthermore, the drug storage and release layer may be one or two pieces, with the two drug storage and release layers arranged at intervals corresponding to the eye.

[0015] The beneficial effects of this utility model are:

[0016] 1. This invention delivers medication to the temporal side of both eyes, allowing the medication to pass quickly through the lower lacrimal punctum, thus reducing drug loss.

[0017] 2. Patients do not need to directly face the medicine bottle, reducing their fear and preventing accidental contact with the eyes, which could contaminate the bottle and the entire eye drops. This effectively avoids drug contamination and reduces medication costs for patients.

[0018] 3. This utility model is a disposable product, which is highly comfortable, easy to operate, and can be used in conjunction with most liquid medicines, making it highly applicable.

[0019] 4. This invention can increase the effective duration and concentration of medication applied to the eyelid margin, making it more effective for patients with blepharitis compared to traditional spot application methods.

[0020] 5. This utility model is convenient, versatile, and can also be used for cleaning the conjunctival sac and eyelid margin.

[0021] 6. This utility model can be used as a carrier for various drugs and has wide applicability.

[0022] 7. This utility model can be extended to be used as a release carrier for surgical and dermatological drugs, increasing the effective time of the drug. Attached Figure Description

[0023] To more clearly illustrate the technical solutions in the embodiments of this utility model or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of this utility model. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0024] Figure 1 This is an exploded view of the present invention;

[0025] Figure 2 This is a schematic diagram of the structure of this utility model.

[0026] The diagram includes the following labels: 1-Main base layer, 2-Waterproof isolation layer, 3-Drug storage and release layer, 31-Base layer, 32-Upper layer, 4-Cleaning and protective layer. Detailed Implementation

[0027] The technical solutions of the present utility model will be clearly and completely described below with reference to the accompanying drawings of the embodiments. Obviously, the described embodiments are only some embodiments of the present utility model, and not all embodiments. Based on the embodiments of the present utility model, all other embodiments obtained by those of ordinary skill in the art without creative effort are within the protection scope of the present utility model.

[0028] Reference Figure 1-2 A novel ophthalmic drug delivery system comprises, from the outside in, a main body base 1 and a waterproof isolation layer 2 fixedly bonded together. At least one drug storage and release layer 3 is bonded to the waterproof isolation layer 2. The drug storage and release layer 3 stores ophthalmic medication and releases it into the eye upon contact. The drug storage and release layer includes a base layer 31 and an upper layer 32 bonded together. The base layer 31 is a methylcellulose layer, and the upper layer 32 is a polycaprolactone layer. The waterproof isolation layer 2 prevents water and bacteria from the hands from entering the drug storage and release layer 3 through the main body base 1 during use, ensuring hygiene and cleanliness.

[0029] As a further implementation, a cleaning and protective layer 4 is also attached to the waterproof isolation layer 2. The cleaning and protective layer 4 is used to clean the eyes after water is applied. The cleaning and protective layer is generally made of medical non-woven fabric or medical cotton cloth, which is softer and has a better feel than the waterproof isolation layer. When eye drops or other medications are applied to the drug storage and release layer 3 and the medication is released by pressing on the eye, it can prevent the waterproof isolation layer 2 from accidentally coming into contact with the eyes, thus better protecting the eyes.

[0030] As a further implementation, the main base layer 1, the waterproof isolation layer 2, and the cleaning and protective layer 4 have the same shape. Specifically, the main base layer 1 can be goggle-shaped or elliptical. The drug storage and release layer 3 can be one or two pieces. When the drug storage and release layer 3 is one piece, the main base layer 1 can be elliptical; when the drug storage and release layer 3 is two pieces, the main base layer 1 can be goggle-shaped. The drug storage and release layers 3 are spaced apart to correspond to the eyes. The drug storage and release layer 3 can be elliptical or circular.

[0031] As a further implementation scheme, the main base layer 1 is a printed fabric, non-woven fabric, plain fabric, or elastic fabric.

[0032] As a further implementation, the waterproof isolation layer 2 is a PU film, PE film, or PP film.

[0033] Method 1 of using this utility model: Take out medical eye drops or other medications and drop them onto the drug storage and release layer 3. Generally, 0.2ml-0.3ml is sufficient. Place the drug storage and release layer 3 of this utility model on the temporal side of the eye and press the drug storage and release layer 3 to release the medication into the conjunctival sac.

[0034] Method 2 of using this utility model: Drip purified water into the cleaning and protective layer 4, wipe the eyelid margin or conjunctival sac with the cleaning and protective layer 4, take out medical eye drops or other medications and drip them onto the drug storage and release layer 3, generally 0.2ml-0.3ml is enough, press the drug storage and release layer 3, and the medication will be released into the conjunctival sac.

[0035] This invention administers medication to the temporal side of both eyes, allowing the drug to quickly pass through the lower lacrimal punctum, minimizing drug loss. Patients do not need to directly face the bottle, reducing fear and preventing accidental contact with the eye, thus avoiding contamination of the entire eye drops and reducing medication costs. This invention is a disposable product, offering high comfort and ease of use. It can be used with most medications, making it highly versatile. This invention increases the effective duration and concentration of medication applied to the eyelid margin, providing higher effectiveness for patients with blepharitis compared to traditional methods. This invention is convenient, versatile, and can also be used for cleaning the conjunctival sac and eyelid margin. This invention can serve as a carrier for various drugs, offering broad applicability. This invention can be extended to be used as a release carrier for surgical and dermatological drugs, increasing the effective duration of the medication.

[0036] The above description is only a preferred embodiment of the present utility model and is not intended to limit the present utility model. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present utility model should be included within the protection scope of the present utility model.

Claims

1. A novel ocular drug delivery release system characterized in that: From outside to inside, the main body base layer and the waterproof isolation layer are fixedly attached together, at least one drug storage and release layer is attached to the waterproof isolation layer, the drug storage and release layer is used for storing ophthalmic articles and releasing ophthalmic drugs into the eyes when in contact with the eyes, the drug storage and release layer comprises a base layer and an upper layer which are attached together, the base layer is a methyl cellulose layer, and the upper layer is a polycaprolactone layer, and the waterproof isolation layer is used for preventing water and bacteria from entering the drug storage and release layer from the main body base layer.

2. The novel ocular drug delivery release system as claimed in claim 1, wherein: A cleaning protection layer is further attached to the waterproof isolation layer, and the cleaning protection layer is used for cleaning the eyes after dripping water and protecting the eyes from contacting the waterproof isolation layer.

3. The novel ocular drug delivery release system as claimed in claim 2, wherein: The cleaning protection layer is a medical non-woven fabric or a medical cotton cloth.

4. The novel ocular drug delivery release system as claimed in claim 2, wherein: The main body base layer, the waterproof isolation layer and the cleaning protection layer are of the same shape.

5. The novel ocular drug delivery release system as claimed in claim 4, wherein: The main body base layer is in the shape of an eye patch or an ellipse.

6. The novel ocular drug delivery release system as claimed in claim 1, wherein: The main body base layer is printed cloth, non-woven fabric, plain cloth or elastic cloth.

7. The novel ocular drug delivery release system as claimed in claim 1, wherein: The waterproof isolation layer is a PU film, a PE film or a PP film.

8. The novel ocular drug delivery release system as claimed in claim 1, wherein: The drug storage and release layer is in the shape of an ellipse or a circle.

9. The novel ocular drug delivery release system as claimed in claim 1, wherein: The drug storage and release layer is one or two, and the two drug storage and release layers are arranged in correspondence with the eyes.

Images